ALX ONCOLOGY HLDGS INC's ticker is ALXO and the CUSIP is 00166B105. A total of 58 filers reported holding ALX ONCOLOGY HLDGS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 2.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $51,830 | -33.7% | 10,798 | +3.7% | 0.00% | – |
| Q2 2023 | $78,202 | +67.1% | 10,413 | +0.6% | 0.00% | – |
| Q1 2023 | $46,796 | -59.1% | 10,353 | +2.0% | 0.00% | -100.0% |
| Q4 2022 | $114,357 | +17.9% | 10,147 | -0.4% | 0.00% | 0.0% |
| Q3 2022 | $97,000 | +19.8% | 10,184 | +1.4% | 0.00% | 0.0% |
| Q2 2022 | $81,000 | -45.6% | 10,040 | +14.1% | 0.00% | 0.0% |
| Q1 2022 | $149,000 | -26.2% | 8,803 | -6.6% | 0.00% | 0.0% |
| Q4 2021 | $202,000 | -71.8% | 9,422 | -2.9% | 0.00% | -75.0% |
| Q3 2021 | $717,000 | +32.0% | 9,705 | -2.3% | 0.00% | +100.0% |
| Q2 2021 | $543,000 | -27.6% | 9,935 | -2.3% | 0.00% | -33.3% |
| Q1 2021 | $750,000 | +53.7% | 10,168 | +79.6% | 0.00% | +50.0% |
| Q4 2020 | $488,000 | +125.9% | 5,660 | -1.1% | 0.00% | +100.0% |
| Q3 2020 | $216,000 | – | 5,724 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| venBio Partners LLC | 9,699,925 | $163,929,000 | 36.34% |
| Logos Global Management LP | 3,011,352 | $50,892,000 | 6.60% |
| Vivo Capital, LLC | 4,220,048 | $71,319,000 | 4.91% |
| Samsara BioCapital, LLC | 262,786 | $4,441,000 | 1.12% |
| Cormorant Asset Management, LP | 712,079 | $12,034,000 | 0.92% |
| Pier Capital, LLC | 394,443 | $6,666,000 | 0.85% |
| Redmile Group, LLC | 772,397 | $13,054,000 | 0.41% |
| Artal Group S.A. | 500,000 | $8,450,000 | 0.35% |
| Nan Fung Group Holdings Ltd | 41,950 | $709,000 | 0.34% |
| Orbimed Advisors | 621,700 | $10,507,000 | 0.17% |